Use of111in-bleomycin for combining radiotherapy and chemotherapy on glioma-bearing mice

Publisher Website
Google Scholar
Abstract
Mice bearing transplanted glioma received 0.9% NaCl, 0.1 mg of BLM, or 200–250 μCi of 111 In‐BLM (0.1 mg BLM) daily for 5 days intraperitoneally. After therapy, tumor sizes were in the order NaCl > BLM > 111 In‐BLM. On the 11th day after the first injection, tumor size (mm3) in the 111 In‐BLM group was 1,220; in the BLM group, it was 2,310 (P < .025). After intratumor injection of a total dose of 0.1 mg of BLM/gm tumor weight, or of 1 mCi/gm tumor weight of 111 In‐BLM (carried by 0.1 mg of BLM/gm tumor weight), the tumor size decreased in the 111 In‐BLM group more than in the BLM group. On the 5th day after the 2nd dose therapy, the tumor size in the 111 In‐BLM group was 2,020; in the BLM group it was 4,220 (P < .05). Host weights for these two groups were similar. The necrotic area in the tumor was much greater in the 111 In‐BLM group than in the BLM group. These results suggest the use for radiotherapy and chemotherapy.

This publication has 14 references indexed in Scilit: